✦ LIBER ✦

AR2 A COST-EFFECTIVENESS ANALYSIS OF BIOLOGICAL TREATMENTS FOR RHEUMATOID ARTHRITI ARTHRITIS

✍ Scribed by CF Chiou; L Wanke; E Yu; J Ofman

Book ID: 119592993
Publisher: John Wiley and Sons
Year: 2004
Tongue: English
Weight: 56 KB
Volume: 7
Category: Article
ISSN: 1098-3015
DOI: 10.1016/s1098-3015(10)62076-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cost-effectiveness analysis of biologica

Cost-effectiveness analysis of biological treatments for rheumatoid arthritis

✍ Chiou, Chiun-Fang; Choi, Julie; Reyes, Carolina M 📂 Article 📅 2004 🏛 Expert Reviews 🌐 English ⚖ 102 KB

Why are the findings of cost-effectivene

Why are the findings of cost-effectiveness analyses of biologic treatment for rheumatoid arthritis so different?

✍ Druyts, E.; Thorlund, K.; Mills, E. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB

Biologic drugs for rheumatoid arthritis

Biologic drugs for rheumatoid arthritis in the medicare program: A cost-effectiveness analysis

✍ Allan J. Wailoo; Nick Bansback; Alan Brennan; Kaleb Michaud; Richard M. Nixon; F 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 96 KB 👁 2 views

PMS13 COST EFFECTIVENESS OF BIOLOGICS FO

PMS13 COST EFFECTIVENESS OF BIOLOGICS FOR RHEUMATOID ARTHRITIS: A SYSTEMATIC REVIEW

✍ B Pham; K McMartin; M Bornstein; M Machado; C Bombardier; MD Krahn; L Levin 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB

Cost-effectiveness of biologic treatment

Cost-effectiveness of biologic treatment for rheumatoid arthritis in clinical practice: An achievable target?

✍ Modena, Vittorio; Bianchi, Gerolamo; Roccatello, Dario 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 155 KB

A cost-effectiveness analysis of treatme

A cost-effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis

✍ Hyon K. Choi; John D. Seeger; Karen M. Kuntz 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 106 KB 👁 2 views

## Objective: Recently, new treatment options for rheumatoid arthritis (ra) patients with an inadequate response to methotrexate (mtx) have become available. given the wide variability in efficacy and costs among these different treatment options, we sought to determine their cost-effectiveness (ce